Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Pulmozyme

Executive Summary

Safety data in patients three months to five years old added to labeling Feb. 24. In the pediatric study for dornase alfa inhalation solution for cystic fibrosis, 98 patients - 65 aged three months to under five years and 33 aged from five through 10 years - received 2.5 mg Pulmozyme for two weeks. Patients from the younger group showed a higher rate of cough (45% vs. 30%) and moderate to severe cough (37% vs. 18%), as well as rhinitis (35% vs. 27%) and rash (6% vs. 0%)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel